COMMUNIQUÉS West-GlobeNewswire

60 Degrees Pharmaceuticals Announces 2025 Annual Results
31/03/2026
FY 2025 net product revenues increased 65% to $1,005,000 Current shelf capacity exhausted after raise of $4 million through an ATM facility WASHINGTON, March 31, 2026 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc [...]
4basebio announces major expansion to support the growing demand of RUO and HQ synthetic DNA with lease of an innovation hub and manufacturing facility in Cambridge, UK
31/03/2026
4basebio PLC ("4basebio" or the "Company") Cambridge, UK, 31 March 2026 – 4basebio PLC (AIM: 4BB), a specialist in synthetic DNA manufacturing and nucleic acids for next-generation therapeutics, announces a significant [...]
Biomea Fusion Announces First Patient Dosed in Newly Initiated Phase II Programs Enrolling Type 2 Diabetes Patients Failing on Standard-of-Care Therapies
31/03/2026
COVALENT-211 Phase II enrolling insulin-deficient type 2 diabetes patients COVALENT-212 Phase II enrolling type 2 diabetes patients uncontrolled with a GLP-1 receptor agonist-based therapy Topline 26-week primary [...]
Atos Advances AI-Ready Digital Transformation with Lumen Network as a Service
31/03/2026
Atos Advances AI-Ready Digital Transformation with Lumen Network as a Service Irving, Texas, USA – March 31, 2026 – Atos , a global leader of AI-powered digital transformation today announced a significant advancement [...]
Kamada Updates on Withholding Tax Procedures on Previously Announced Cash Dividend to Shareholders
31/03/2026
REHOVOT, Israel and HOBOKEN, N.J., March 31, 2026 (GLOBE NEWSWIRE) -- Kamada Ltd. (the “Company”) (NASDAQ: KMDA; TASE: KMDA.TA), a global biopharmaceutical company with a portfolio of marketed products indicated for [...]
American Shared Hospital Services Reports Fourth Quarter and Full Year 2025 Financial Results
31/03/2026
Announces Seven Year Extension of Proton Therapy Lease Agreement with Orlando Health Through 2033 Conference Call Scheduled for 12:00 PM ET Today SAN FRANCISCO, March 31, 2026 (GLOBE NEWSWIRE) -- American Shared [...]
Shock Top Launches High Voltage, Its First-Ever High-ABV Beer
31/03/2026
A Double Wheat Brew that Surges with Big, Shocking Citrus, Shock Top High Voltage is Boldly Strong at 9.6% ABV PORTLAND, Ore., March 31, 2026 (GLOBE NEWSWIRE) -- Shock Top , a craft beer icon and brand by Tilray [...]
Oculis Announces European Medicines Agency PRIME Designation for Privosegtor, Advancing a Potential First‑in‑Class Neuroprotective Candidate for Optic Neuritis
31/03/2026
ZUG, Switzerland, March 31, 2026 (GLOBE NEWSWIRE) -- PRIME designation follows recent Breakthrough Therapy designation from the U.S. FDA, underscoring the importance and urgency of addressing optic neuritis, a serious [...]
LENSAR® Reports Fourth Quarter and Full Year 2025 Results and Provides Business Update
31/03/2026
15 ALLY Robotic Cataract Laser Systems® (“ALLY Systems”) placed in 4Q 2025; Backlog of 13 ALLY Systems pending installation as of December 31, 2025 ALLY installed base grew 48%, total laser installed base grew 13% over [...]
Beta Bionics Introduces Bionic Insights™ in Bionic Reports — Transforming How Clinicians Understand and Optimize Diabetes Care
31/03/2026
Advanced report intelligence delivers actionable guidance to improve outcomes for people using the iLet Bionic Pancreas IRVINE, Calif., March 31, 2026 (GLOBE NEWSWIRE) -- Beta Bionics today announced the launch of [...]
Fennec Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
31/03/2026
RESEARCH TRIANGLE PARK, N.C., March 31, 2026 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC) (TSX:FRX) (“Fennec” or the “Company”), a specialty pharmaceutical company, today announced that on March 17, [...]
KDIGO publishes 2026 Clinical Practice Guideline Draft for Acute Kidney Injury and Acute Kidney Disease
31/03/2026
March 31, 2026 News Release KDIGO publishes 2026 Clinical Practice Guideline Draft for Acute Kidney Injury and Acute Kidney Disease COPENHAGEN, DENMARK, 31 March 2026 – BioPorto A/S (“BioPorto” or “Company”) (CPH: [...]
SCYNEXIS Announces $40.0 Million Private Placement
31/03/2026
JERSEY CITY, N.J., March 31, 2026 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX ) (“SCYNEXIS” or the “Company”), a biotechnology company focused on developing innovative new therapies to address severe rare diseases [...]
SCYNEXIS Completes Transformative Acquisition of PXL-770, an innovative, highly selective, direct AMPK activator for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
31/03/2026
PXL-770 (now SCY-770) is a clinical stage, well-characterized oral therapy designed to address the underlying drivers of ADPKD by reducing cyst growth and disease progression A Phase 2 proof-of-concept study of SCY-770 [...]
Agios Advances Mitapivat Toward Potential U.S. Accelerated Approval in Sickle Cell Disease Following Pre-sNDA Meeting with FDA
31/03/2026
Company has already submitted proposed confirmatory trial for FDA review, as required under accelerated approval pathway Company plans to submit mitapivat sNDA in sickle cell disease in the coming months, and is [...]
Biogen to Acquire Apellis, Enhancing the Company’s Growth Portfolio in Immunology and Rare Disease, Bolstering Growth Outlook and Accelerating Expansion into Nephrology
31/03/2026
Acquisition will bring two differentiated commercialized immunology medicines to Biogen with EMPAVELI ® FDA-approved in three indications, including two rare kidney diseases, and SYFOVRE ® FDA-approved in geographic [...]
Tonix Pharmaceuticals Announces Presentation of Phase 1 Data and Outlines Planned Adaptive Phase 2 Field Study of TNX-4800 for the Prevention of Lyme Disease, at the World Vaccine Congress Washington 2026
31/03/2026
TNX-4800 is a long-acting anti-Borrelia burgdorferi OspA human monoclonal antibody in development as a single-dose Lyme prophylactic Phase 1 study of TNX-4800 demonstrated safety, tolerability, and pharmacokinetics [...]
CancerVax Reports Successful Initial Mouse Study with Breakthrough Results
31/03/2026
First biodistribution study of the Company’s novel targeted lipid nanoparticle achieved systemic circulation with the potential to target many types of cancer Lehi, UT, March 31, 2026 (GLOBE NEWSWIRE) -- Lehi, Utah, [...]
EURneffy 1 mg approved across the EU as the first and only needle-free adrenaline treatment for young children (≥15 kg) at risk of anaphylaxis
31/03/2026
Today, ALK announced that children aged 4 and older living with severe allergies across the EU can now access the first and only needle-free adrenaline treatment for anaphylaxis, after the European Commission (EC) [...]

Pages